Lead Product(s): Hypoimmunogenic cells
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 29, 2020
First research collaboration for immunotolerance UniverCyteTM technology platform, marking launch of new business development and collaboration strategy.